Vaccine Effectiveness Charts

Important update: Healthcare facilities

CDC has updated select ways to operate healthcare systems effectively in response to COVID-19 vaccination. Learn more

Find the latest information:
Recommendations for Fully Vaccinated People
COVID-19 Homepage

UPDATE

Given new evidence on the B.1.617.2 (Delta) variant, CDC has updated the guidance for fully vaccinated people. CDC recommends universal indoor masking for all teachers, staff, students, and visitors to K-12 schools, regardless of vaccination status. Children should return to full-time in-person learning in the fall with layered prevention strategies in place.

UPDATE

The White House announced that vaccines will be required for international travelers coming into the United States, with an effective date of November 8, 2021. For purposes of entry into the United States, vaccines accepted will include FDA approved or authorized and WHO Emergency Use Listing vaccines. More information is available here.

UPDATE

Travel requirements to enter the United States are changing, starting November 8, 2021. More information is available here.

Español | Other Languages

Primary Series Vaccine Effectiveness Against Hospitalization (All Studies)

Primary Series Vaccine Effectiveness Against Hospitalization (All Studies) Data Table
Data as of 05/04/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	06/01/21	07/01/21	06/16/21	84.0	80.0	88.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	03/01/21	05/01/21	03/31/21	86.0	81.0	89.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	08/01/21	09/01/21	08/16/21	87.0	85.0	89.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	10/01/21	11/01/21	10/16/21	83.0	79.0	86.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	12/01/21	12/31/21	12/15/21	84.0	77.0	89.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	01/01/22	01/31/22	01/15/22	59.0	41.0	71.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	02/01/22	03/31/22	03/01/22	47.0	25.0	63.0	VE Against Hospitalization
Overcoming (12 to 18 year olds)	Hospitalization (SARS-CoV-2-pos)	12 – 18 years	Pfizer	07/01/21	12/01/21	09/15/21	91.0	88.0	94.0	VE Against Hospitalization
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	02/01/21	06/01/21	04/02/21	85.1	75.0	91.1	VE Against Hospitalization
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	07/01/21	08/01/21	07/16/21	83.3	75.6	88.6	VE Against Hospitalization
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	09/01/21	12/01/21	10/18/21	83.0	74.7	88.6	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	03/01/21	04/01/21	03/16/21	88.0	85.0	90.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	05/01/21	06/01/21	05/16/21	89.0	88.0	91.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	07/01/21	08/01/21	07/16/21	89.0	88.0	90.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	09/01/21	10/01/21	09/16/21	87.0	86.0	88.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	11/01/21	12/01/21	11/16/21	86.0	85.0	87.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	01/01/22	1/31/2022	1/15/2022	55.0	50.0	60.0	VE Against Hospitalization

Dates are approximate

Download Data [10 KB, XLSX]

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors* related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant. VE estimates prior to July 2021 represent a mix of circulating variants.
*All analyses adjust for time, region/study site, age, sex, race/ethnicity. VISION estimates also adjust for additional factors related to a person’s likelihood of vaccination.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_2aa95996_453757′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453757′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart01′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453757/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 12 Years and Older by Age Group (All Studies)

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 12 Years and Older by Age Group (All Studies) Data Table
Data as of 04/18/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	03/01/21	05/01/21	03/31/21	87.0	81.0	92.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	06/01/21	07/01/21	06/16/21	86.0	81.0	90.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	08/01/21	09/01/21	08/16/21	90.0	87.0	92.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	10/01/21	11/01/21	10/16/21	85.0	80.0	88.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	12/01/21	12/31/21	12/15/21	87.0	79.0	92.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	03/01/21	05/01/21	03/28/21	85.0	78.0	89.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	06/01/21	07/01/21	06/13/21	81.0	73.0	87.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	08/01/21	09/01/21	08/13/21	83.0	78.0	87.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	10/01/21	11/01/21	10/13/21	83.0	76.0	88.0	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	12/01/21	12/31/21	12/12/21	77.0	60.0	87.0	VE Against Hospitalization by Age Group
Overcoming	Hospitalization (SARS-CoV-2-pos)	12 – 15 years	Pfizer	07/01/21	12/01/21	09/15/21	91.0	88.0	95.0	VE Against Hospitalization by Age Group
Overcoming	Hospitalization (SARS-CoV-2-pos)	16 – 18 years	Pfizer	07/01/21	12/01/21	09/12/21	93.0	87.0	96.0	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	02/01/21	06/01/21	04/02/21	95.1	82.7	98.6	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	07/01/21	08/01/21	07/16/21	91.4	82.6	95.7	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	09/01/21	12/01/21	10/16/21	90.2	79.7	95.2	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	02/01/21	06/01/21	03/30/21	76.8	57.4	87.4	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	07/01/21	08/01/21	07/13/21	75.4	60.7	84.7	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	09/01/21	12/01/21	10/13/21	79.7	65.9	88.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	03/01/21	04/01/21	03/16/21	88.0	84.0	91.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	05/01/21	06/01/21	05/16/21	91.0	90.0	93.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	07/01/21	08/01/21	07/16/21	91.0	90.0	92.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	09/01/21	10/01/21	09/16/21	90.0	89.0	90.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	11/01/21	12/01/21	11/16/21	89.0	88.0	90.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	03/01/21	04/01/21	03/13/21	89.0	85.0	91.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	05/01/21	06/01/21	05/13/21	83.0	79.0	87.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	07/01/21	08/01/21	07/13/21	82.0	79.0	84.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	09/01/21	10/01/21	09/13/21	82.0	79.0	84.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	11/01/21	12/01/21	11/13/21	82.0	80.0	84.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	All vaccines	01/01/22	02/28/22	02/01/22	63.0	56.0	69.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	65 years and older	All vaccines	01/01/22	02/28/22	01/30/22	69.0	62.0	74.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	All vaccines	03/01/22	03/31/22	03/15/22	62.0	40.0	76.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	65 years and older	All vaccines	03/01/22	03/31/22	03/16/22	75.0	63.0	83.0	VE Against Hospitalization by Age Group

Dates are approximate

Download Data [7 KB, XLSX]

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_f09aabfb_453758′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453758′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart02′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453758/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization Among Adults Ages 18 Years and Older by Age Group (IVY)

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 18 Years and Older by Age Group (IVY) Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	03/01/21	05/01/21	03/31/21	87	81	92	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	06/01/21	07/01/21	06/16/21	86	81	90	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	08/01/21	09/01/21	08/16/21	90	87	92	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	10/01/21	11/01/21	10/16/21	85	80	88	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	mRNA	12/01/21	12/31/21	12/15/21	87	79	92	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	03/01/21	05/01/21	03/28/21	85	78	89	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	06/01/21	07/01/21	06/13/21	81	73	87	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	08/01/21	09/01/21	08/13/21	83	78	87	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	10/01/21	11/01/21	10/13/21	83	76	88	VE Against Hospitalization by Age Group
IVY	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	12/01/21	12/31/21	12/12/21	77	60	87	VE Against Hospitalization by Age Group

Dates are approximate

Download Data [6 KB, XLSX]

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors, including region/study site, age, sex, and race/ethnicity, related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_0707c6db_453759′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453759′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart03′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453759/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 12 to 18 Years by Age Group (Overcoming)

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 12 to 18 Years by Age Group (Overcoming) Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
Overcoming	Hospitalization (SARS-CoV-2-pos)	12 – 15 years	Pfizer	07/01/21	12/01/21	09/15/21	91	88	95	VE Against Hospitalization by Age Group
Overcoming	Hospitalization (SARS-CoV-2-pos)	16 – 18 years	Pfizer	07/01/21	12/01/21	09/12/21	93	87	96	VE Against Hospitalization by Age Group

Dates are approximate

Download Data [6 KB, XLSX]

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors, including region/study site, age, sex, and race/ethnicity, related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_87081727_453773′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453773′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart04′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453773/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization Among Adults Ages 18 Years and Older by Age Group (SUPERNOVA)

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 18 Years and Older by Age Group (SUPERNOVA)
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18-64 years	mRNA	02/01/21	06/01/21	04/02/21	95.1	82.7	98.6	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18-64 years	mRNA	07/01/21	08/01/21	07/16/21	91.4	82.6	95.7	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18-64 years	Pfizer	09/01/21	12/01/21	10/16/21	90.2	79.7	95.2	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	02/01/21	06/01/21	03/30/21	76.8	57.4	87.4	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	07/01/21	08/01/21	07/13/21	75.4	60.7	84.7	VE Against Hospitalization by Age Group
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	65 years and older	mRNA	09/01/21	12/01/21	10/13/21	79.7	65.9	88.0	VE Against Hospitalization by Age Group

Dates are approximate

Download Data [10 KB, XLSX]

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors, including region/study site, age, sex, and race/ethnicity, related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_e6ef1762_453774′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453774′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart05′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453774/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 18 Years and Older by Age Group (VISION)

Primary Series Vaccine Effectiveness Against Hospitalization Among People Ages 18 Years and Older by Age Group (VISION)
Data as of 4/18/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	03/01/21	04/01/21	03/16/21	88.0	84.0	91.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	05/01/21	06/01/21	05/16/21	91.0	90.0	93.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	07/01/21	08/01/21	07/16/21	91.0	90.0	92.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	09/01/21	10/01/21	09/16/21	90.0	89.0	90.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 74 years	All vaccines	11/01/21	12/01/21	11/16/21	89.0	88.0	90.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	03/01/21	04/01/21	03/13/21	89.0	85.0	91.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	05/01/21	06/01/21	05/13/21	83.0	79.0	87.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	07/01/21	08/01/21	07/13/21	82.0	79.0	84.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	09/01/21	10/01/21	09/13/21	82.0	79.0	84.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	75 years and older	All vaccines	11/01/21	12/01/21	11/13/21	82.0	80.0	84.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	All vaccines	01/01/22	02/28/22	02/01/22	63.0	56.0	69.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	65 years and older	All vaccines	01/01/22	02/28/22	01/30/22	69.0	62.0	74.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	All vaccines	03/01/22	03/31/22	03/15/22	62.0	40.0	76.0	VE Against Hospitalization by Age Group
VISION	Hospitalization (SARS-CoV-2-pos)	65 years and older	All vaccines	03/01/22	03/31/22	03/16/22	75.0	63.0	83.0	VE Against Hospitalization by Age Group

Dates are approximate

Download Data [6 KB, XLSX]

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19.) –><div class=’rid_03531572_453775′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453775′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart06′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453775/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults Ages 18 Years and Older (All Studies)

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults 18 Years and Older (All Studies) Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	03/01/21	05/01/21	04/02/21	89.0	84.0	93.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	06/01/21	07/01/21	06/18/21	90.0	85.0	93.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	08/01/21	09/01/21	08/18/21	90.0	88.0	92.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	10/01/21	11/01/21	10/18/21	87.0	82.0	90.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	12/01/21	12/31/21	12/17/21	85.0	76.0	91.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	03/01/21	05/01/21	03/29/21	83.0	76.0	88.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	06/01/21	07/01/21	06/14/21	80.0	75.0	85.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	08/01/21	09/01/21	08/14/21	84.0	81.0	87.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	10/01/21	11/01/21	10/14/21	80.0	75.0	84.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	12/01/21	12/31/21	12/13/21	83.0	75.0	88.0	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	02/01/21	06/01/21	04/04/21	84.7	67.5	92.8	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	07/01/21	08/01/21	07/18/21	87.1	76.9	92.8	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	09/01/21	12/01/21	10/18/21	89.8	81.0	94.5	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	02/01/21	06/01/21	03/31/21	84.7	70.9	92.0	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	07/01/21	08/01/21	07/14/21	78.7	67.3	86.1	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	09/01/21	12/01/21	10/14/21	76.5	63.2	85.0	VE Against Hospitalization by Vaccine Product
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	06/21/21	08/21/21	07/23/21	95.0	92.0	97.0	VE Against Hospitalization by Vaccine Product
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	06/21/21	08/21/21	07/19/21	80.0	73.0	85.0	VE Against Hospitalization by Vaccine Product
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	J&J	06/21/21	08/21/21	07/21/21	60.0	31.0	77.0	VE Against Hospitalization by Vaccine Product

Dates are approximate

Download Data

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_a0f24f96_453777′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453777′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart07′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453777/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults Ages 18 Years and Older (IVY)

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults 18 Years and Older (IVY) Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	03/01/21	05/01/21	04/02/21	89.0	84.0	93.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	06/01/21	07/01/21	06/18/21	90.0	85.0	93.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	08/01/21	09/01/21	08/18/21	90.0	88.0	92.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	10/01/21	11/01/21	10/18/21	87.0	82.0	90.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	12/01/21	12/31/21	12/17/21	85.0	76.0	91.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	03/01/21	05/01/21	03/29/21	83.0	76.0	88.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	06/01/21	07/01/21	06/14/21	80.0	75.0	85.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	08/01/21	09/01/21	08/14/21	84.0	81.0	87.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	10/01/21	11/01/21	10/14/21	80.0	75.0	84.0	VE Against Hospitalization by Vaccine Product
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	12/01/21	12/31/21	12/13/21	83.0	75.0	88.0	VE Against Hospitalization by Vaccine Product

Dates are approximate

Download Data

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors, including region/study site, age, sex, and race/ethnicity, related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant. VE estimates prior to July 2021 represent a mix of circulating variants.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_4914e58c_453778′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453778′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart08′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453778/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults Ages 18 Years and Older (SUPERNOVA)

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults 18 Years and Older (SUPERNOVA) Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	02/01/21	06/01/21	04/04/21	84.7	67.5	92.8	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	07/01/21	08/01/21	07/18/21	87.1	76.9	92.8	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	09/01/21	12/01/21	10/18/21	89.8	81.0	94.5	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	02/01/21	06/01/21	03/31/21	84.7	70.9	92.0	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	07/01/21	08/01/21	07/14/21	78.7	67.3	86.1	VE Against Hospitalization by Vaccine Product
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	09/01/21	12/01/21	10/14/21	76.5	63.2	85.0	VE Against Hospitalization by Vaccine Product

Dates are approximate

Download Data

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors, including region/study site, age, sex, and race/ethnicity, related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant. VE estimates prior to July 2021 represent a mix of circulating variants.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_7c86203d_453792′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453792′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart09′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453792/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults Ages 18 Years and Older (VISION)

Primary Series Vaccine Effectiveness Against Hospitalization by Vaccine Product Among Adults 18 Years and Older (VISION) Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	Moderna	06/21/21	08/21/21	07/23/21	95.0	92.0	97.0	VE Against Hospitalization by Vaccine Product
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	Pfizer	06/21/21	08/21/21	07/19/21	80.0	73.0	85.0	VE Against Hospitalization by Vaccine Product
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	J&J	06/21/21	08/21/21	07/21/21	60.0	31.0	77.0	VE Against Hospitalization by Vaccine Product

Dates are approximate

Download Data

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_db8ba245_453793′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453793′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart10′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453793/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Infection

Primary Series Vaccine Effectiveness Against Infection Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
HEROES/RECOVER (18 years and older)	All infection	18 years and older	All vaccines	01/21/21	06/01/21	03/27/21	91.0	81.0	96.0	VE Against Infection
HEROES/RECOVER (18 years and older)	All infection	18 years and older	All vaccines	07/01/21	08/01/21	07/16/21	66.0	26.0	84.0	VE Against Infection
HEROES/RECOVER (18 years and older)	All infection	18 years and older	All vaccines	08/31/21	10/01/21	09/15/21	67.0	48.0	80.0	VE Against Infection
NHSN (Nursing home residents)	All infection	.	mRNA	03/01/21	04/01/21	03/16/21	72.9	67.7	77.2	VE Against Infection
NHSN (Nursing home residents)	All infection	.	mRNA	05/01/21	06/01/21	05/16/21	69.6	62.9	75.1	VE Against Infection
NHSN (Nursing home residents)	All infection	.	mRNA	07/01/21	08/01/21	07/14/21	58.6	56.9	60.3	VE Against Infection
PROTECT (12 to 17 year olds)	All infection	12 – 17 years	Pfizer	07/01/21	12/01/21	09/15/21	92.0	79.0	97.0	VE Against Infection
PROTECT (12 to 15 year olds)	Symptomatic infection	12 – 15 years	Pfizer	12/01/21	12/31/21	12/15/21	81.0	51.0	93.0	VE Against Infection
PROTECT (12 to 15 year olds)	Symptomatic infection	12 – 15 years	Pfizer	01/01/22	02/01/22	01/15/22	59.0	24.0	78.0	VE Against Infection
PROTECT (5 to 11 year olds)	Symptomatic infection	5 – 11 years	Pfizer	01/01/22	02/01/22	01/15/22	31.0	9.0	48.0	VE Against Infection

Dates are approximate

Download Data

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors* related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant. VE estimates prior to July 2021 represent a mix of circulating variants.
* NHSN estimates are for long-term care residents and adjust for calendar week. HEROES/RECOVER estimates adjust for local virus circulation, study location, occupation, ethnicity, and additional factors related to a person’s likelihood of vaccination. PROTECT estimates adjust for sociodemographic characteristics, chronic conditions and daily medication use, frequency of social contact, mask use, location, and local virus circulation.
This specific NHSN metric will not be updated beyond August 2021 and will be replaced by NHSN metrics estimating the benefits of booster doses.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19. ) –><div class=’rid_61d71cf2_453794′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453794′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart11′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453794/noscript’>source URL</a>.</noscript>

Primary Series Vaccine Effectiveness Against Infection by Vaccine Product Among Nursing Home and Long-Term Care Facility Residents

Primary Series Vaccine Effectiveness Against Infection by Vaccine Product Among Nursing Home and Long-Term Care Facility Residents Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
NHSN	All infection	.	Pfizer	03/01/21	04/01/21	03/14/21	72.1	66.3	76.9	VE Against Infection by Product
NHSN	All infection	.	Pfizer	05/01/21	06/01/21	05/14/21	67.9	60.3	74.1	VE Against Infection by Product
NHSN	All infection	.	Moderna	03/01/21	04/01/21	03/16/21	75.1	67.2	81.1	VE Against Infection by Product
NHSN	All infection	.	Moderna	05/01/21	06/01/21	05/16/21	70.0	59.7	77.6	VE Against Infection by Product
NHSN	All infection	.	Pfizer	07/01/21	08/01/21	07/14/21	56.4	54.4	58.3	VE Against Infection by Product
NHSN	All infection	.	Moderna	07/01/21	08/01/21	07/16/21	57.3	54.9	59.7	VE Against Infection by Product

Dates are approximate

Download Data

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. NHSN estimates are for long-term care residents and adjust for calendar week. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant. VE estimates prior to July 2021 represent a mix of circulating variants.
This specific NHSN metric will not be updated beyond August 2021 and will be replaced by NHSN metrics estimating the benefits of booster doses.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.

Embed Code:

<!– Markup for HTML (Vaccine Effectiveness: COVID-19 vaccines are protecting people from being hospitalized with COVID-19.) –><div class=’rid_91eef316_453795′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’453795′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart12′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/453795/noscript’>source URL</a>.</noscript>